Abacus

Quick links to important sections

Abacus

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Abacus

Quick Facts

Property Description
Active ingredient Hydroxyzine Hydrochloride (Hydroxyzine Hcl)
Form Tablets, Capsules, Syrup, Injection
Pharmacological class First-generation Antihistamine; Piperazine Derivative
Common use Relief from itching and management of tension/anxiety
Origin Synthetic organic compound

Defining Abacus: Classification and Core Identity

The medication known as Abacus is a prescription-only medicine containing the active ingredient Hydroxyzine, typically administered in the salt form Hydroxyzine Hydrochloride (Hydroxyzine Hcl). The compound is classified as a first-generation antihistamine, a drug class primarily defined by its ability to block the effects of histamine. Chemically, Hydroxyzine is recognized as a synthetic organic compound belonging to the piperazine derivative subgroup. This classification is significant because, unlike newer agents, this first-generation compound readily affects the Central Nervous System (CNS), a characteristic that defines its dual therapeutic profile.

Composition, Forms, and General Therapeutic Purpose

The formulation of Abacus is defined as a single-ingredient product featuring only Hydroxyzine Hcl, along with necessary pharmaceutical excipients. The medication is prepared for both oral and intramuscular (IM) routes of administration, and is widely available in various common dosage forms, including tablets, capsules, and oral liquid preparations such as syrup or suspension. The general therapeutic purpose of Hydroxyzine stems from its dual action: it is an effective Histamine H1-receptor inverse agonist that prevents the symptoms of allergic reactions, and it simultaneously suppresses activity in subcortical areas of the central nervous system. This combined function is clinically recognized for addressing both physical symptoms, such as pruritus (itching), and for promoting a generalized calming effect, thereby helping to relieve tension and general anxiety. Clinical observations indicate that the medication can provide effective symptomatic relief.

Regulatory References

  1. MeSH Descriptor Data (NIH/NLM)
  2. MedlinePlus Drug Information (NIH/NLM)

What side effects are possible with Abacus?

Possible Side Effects and Safety Information

The safety profile of Abacus (Hydroxyzine) is officially documented by regulatory authorities, classifying adverse reactions by frequency and affected physiological systems. As a first-generation agent, the medication commonly produces effects related to the central nervous system and anticholinergic activity. These are typically drowsiness (somnolence), dry mouth, headache, and fatigue, which may be transitory and lessen with continued use.


Official Adverse Reaction Categories

Classification System-Organ Class Examples
Common Nervous System (Drowsiness, Somnolence), Anticholinergic (Dry Mouth, Urinary Retention)
Rare Nervous System (Convulsions, Tremor), Gastrointestinal (Nausea, Vomiting)
Not Known/Postmarketing Cardiac Disorders (QT Prolongation, Torsade de Pointes), Skin (AGEP, Hypersensitivity)

Serious Safety Considerations and Restrictions

The regulatory profile highlights the risk of serious adverse reactions, particularly rare but critical cardiac events such as QT prolongation and Torsade de Pointes (a type of ventricular arrhythmia). Accordingly, the medication is contraindicated in patients with a known history of QT interval prolongation or other cardiac risk factors. Acute Generalized Exanthematous Pustulosis (AGEP) is also documented as a rare, severe skin reaction.

Specific safety considerations apply to certain populations. Use is generally not recommended in older adults due to increased vulnerability to effects like confusion and reduced drug clearance. The medication is also contraindicated in early pregnancy and requires caution or restriction in patients with hepatic or renal impairment.

Overdose and Emergency Response

The official regulatory documentation for Hydroxyzine (Abacus) defines a serious overdose profile centered on both central nervous system (CNS) and cardiovascular toxicity. Documented clinical manifestations of overdosage include profound hypersedation, stupor, and ultimately coma; these signs of CNS depression may be accompanied by signs of excitation such as tremor, agitation, disorientation, and convulsions (seizures). Nausea and vomiting are also listed in official labeling.

The most severe outcomes described in regulatory sources relate to the cardiovascular system, highlighting the potential for QT prolongation on an electrocardiogram (ECG) and the specific, life-threatening arrhythmia known as Torsade de Pointes.

Due to the risk of these severe, documented cardiac and neurological effects, regulatory guidance is explicit: immediate medical attention must be sought for any suspected overdosage. Management is strictly symptomatic and supportive, as no specific antidote is known to regulatory authorities. Officially documented interventions include the close observation of the patient, continuous monitoring of vital signs, and mandatory ECG monitoring. Regulatory labeling also specifically warns that the use of epinephrine (adrenaline) for hypotension is contraindicated. Population-specific notes indicate that the elderly are more susceptible to CNS effects such as confusion and over-sedation due to prolonged drug clearance.

Therapeutic Uses of Abacus

What Abacus Treats: Main Uses and Benefits

The medication is commonly used to provide symptomatic relief across several key therapeutic domains. It is applied for addressing symptoms related to intense and recurring pruritus (itching) associated with various allergic skin conditions, including chronic urticaria (hives) and specific types of dermatitis, and for managing symptoms of generalized nervous tension and anxiety related to emotional distress or psychoneurosis. Additionally, it may be part of supportive assistance during procedures by addressing pre-operative apprehension and restlessness.

In these clinical scenarios, Abacus contributes to easing the overall symptom load and may assist patients during episodes of heightened discomfort by helping them cope more steadily with symptom fluctuations. The medication is relevant when short-term symptomatic assistance is needed and when acute manifestations interfere with function.

“Abacus assists with functional stability by providing supportive relief when distressing symptoms interfere with routine activities.”

Quick Fact: Relief for Heightened Symptoms

Symptom Domain Key Use Patient Benefit
Allergic Skin Symptoms Pruritus (Intense Itching) Contributes to improved day-to-day comfort
Emotional Distress Nervous Tension and Anxiety Helps maintain a sense of stability
Procedural Support Pre-operative Apprehension Supports symptomatic relief from tension

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Abacus?

Eligibility for Abacus (Hydroxyzine Hcl) is strictly defined by regulatory authorities based on population safety and physiological status. The medicine is primarily approved for use in adults and children aged 6 years and older for managing anxiety and pruritus. In some regions, use for pruritus is approved for children as young as 12 months.


Absolute Contraindications

Abacus must not be used by certain populations, as use is formally prohibited due to high risk:

  • Patients with known hypersensitivity to hydroxyzine or related piperazine derivatives.
  • Individuals with a known prolonged QT interval or congenital long QT syndrome.
  • Patients with clinically significant, uncorrected electrolyte imbalance (e.g., hypokalaemia).
  • Pregnant women and breastfeeding mothers.

Populations Requiring Restricted Use

Use is restricted and requires dosage reduction in patients with moderate or severe renal impairment or hepatic impairment (liver dysfunction) due to altered drug clearance. Additionally, older adults (geriatric patients) require a lower initial dose due to increased susceptibility to effects. Patients with risk factors for cardiac arrhythmia, prostatic hypertrophy, or narrow-angle glaucoma must use Abacus only with caution, as formally documented in prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Abacus (Hydroxyzine) has documented interaction patterns based on its pharmacological properties and metabolic pathways, as defined in official regulatory documents.

Pharmacodynamic and Contraindicated Combinations

Co-administration with medicinal products known to prolong the QT interval or induce Torsade de Pointes (TdP) is formally contraindicated due to the risk of serious cardiac effects. This restriction includes specific Class IA/III antiarrhythmics, certain antipsychotics (e.g., Haloperidol, Quetiapine), and certain antibiotics (e.g., Erythromycin, Azithromycin).

An additive effect with CNS depressants (including alcohol, opioids, and benzodiazepines) is documented, requiring that the co-administered CNS depressant dosage be officially reduced. Abacus also formally counteracts the pressor action of Adrenaline and antagonizes the effects of Betahistine.


Metabolic and Procedural Constraints

Abacus acts as an inhibitor of the CYP2D6 enzyme. Furthermore, potent inhibitors of CYP3A4/5 are expected to increase hydroxyzine blood concentrations. Co-administration with Cimetidine has been shown to increase hydroxyzine serum concentration by 36%.

Mandatory timing rules state that Abacus treatment must be stopped at least five days before specific diagnostic procedures, such as allergy skin testing or the Methacholine Bronchial Challenge, to prevent interference with test results. Dosage reductions are also required in patients with hepatic and renal impairment.

Mechanism of Action

Abacus is a selective antagonist that primarily targets the GABA A receptor complex within the central nervous system (CNS). Specifically, it exhibits high affinity for receptor subtypes containing the alpha1 subunit.

Upon binding to an allosteric site on the GABA A receptor, Abacus induces a negative allosteric modulation. This binding event reduces the frequency of GABA-mediated chloride ion channel opening.

The resulting decreased influx of negatively charged chloride ions into the postsynaptic neuron leads to a reduction in membrane hyperpolarization. This less hyperpolarized state functionally lowers the inhibitory tone and promotes neuronal excitability. The overall system-level physiological consequence is a modification of neural circuit activity throughout the CNS, specifically in pathways regulated by this inhibitory neurotransmitter system.

Dosage and Administration Information

How Abacus is Used: Official Administration Guidelines

Abacus (Hydroxyzine Hcl) administration is governed by specific regulatory instructions defining the route, dosing structure, and necessary modifications for proper use, as detailed in official prescribing information.


Administration and Dosage Regimen

The medication is officially approved for use via the oral route (tablets, capsules, and syrup) and through deep intramuscular (IM) injection. The injectable form is strictly reserved for acute settings or when oral intake is not feasible, with the mandate to switch to the oral form as soon as possible. The solution for injection is used without prior dilution. Oral forms can be taken with or without food.

Dosing is typically structured into divided daily doses (e.g., three or four times daily) for maintenance uses such as managing pruritus, or as a single, acute dose for procedural support. For adult anxiety relief, typical doses range from 50 mg to 100 mg per dose, while doses for pruritus usually start at 25 mg per dose, administered in a divided schedule. Continuous use for longer than four months for anxiety has not been assessed in clinical studies and requires reassessment.


Population-Specific Use Adjustments

Official prescribing information requires mandatory dose adjustments in specific patient populations to adhere to administration guidelines. For older adults, a dose reduction is recommended, generally starting at the lower end of the established dosage range. Furthermore, specific dose reductions are mandated for patients with impaired organ function: the total daily dosage must be reduced by 50% in those with moderate or severe renal impairment and reduced by 33% in those with hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Abacus (Hydroxyzine Hcl)

Evidence for Use in Allergic Pruritus (Itching)

Research exploring Abacus for symptoms of itching (pruritus) associated with conditions like chronic urticaria (hives) has primarily been conducted using short-term randomized controlled trials (RCTs) and systematic reviews. These studies, applied in research contexts involving fluctuating symptoms, allow researchers to monitor short-term outcomes. Outcomes monitored include pruritus intensity scores and the severity of skin lesions. Evidence is limited when considering the long-term use for this indication. Long-term effects are not fully established, as follow-up durations were limited in the most rigorous clinical trials. Additionally, comparative evidence is lacking when looking at many of the newer, non-sedating second-generation antihistamine medications across all specific patient groups.

Evidence for Use in Generalized Tension and Anxiety

Abacus was evaluated in studies focusing on its role in providing symptomatic assistance for generalized nervous tension and anxiety. Research has mainly consisted of placebo-controlled RCTs, many of which were conducted in earlier decades. Studies monitored outcomes linked to physiological strain by using standardized tools, such as the Hamilton Rating Scale for Anxiety (HAM-A), to measure anxiety severity. Research highlights changes measured during the study period, with findings indicating that certain patterns of symptom change were observed in the studied populations over time. Evidence is limited regarding the benefits of Abacus in chronic, long-term conditions because its effectiveness beyond a few months is not fully established by formal trials.

Long-Term Study Data and Durability of Response

The current body of research for Abacus is heavily weighted toward examining outcomes related to episodic or acute changes over short time intervals. Data are still emerging, and research has explored responses that reflect daily functioning, but these findings are typically based on limited follow-up durations. There is limited information for long-term outcomes, meaning that the duration over which the initial response may be maintained is not well characterized by existing high-quality evidence.

Frequently Asked Questions (FAQ)

Common questions about Abacus (FAQ)


Q: Is Abacus considered a strong medicine?

Abacus is officially classified as a first-generation antihistamine. This class of medicine is noted for its ability to affect the central nervous system (CNS), a characteristic that differentiates it from newer antihistamines. Official documents define its primary action as an H1-receptor inverse agonist, which contributes to its use for relieving tension and anxiety in addition to its use for itching.


Q: How long do the effects of Abacus last?

According to official regulatory information, the clinical effects of Abacus may begin within 15 to 30 minutes after taking the oral form. The maximum concentration of the drug in the body typically occurs about two hours after the dose. Its elimination half-life is approximately 20 hours in adults, which describes how long the drug stays in the body.


Q: Can Abacus interact with common pain relievers?

Regulatory labeling states that the potentiating (enhancing) action of Abacus must be considered when it is used alongside Central Nervous System (CNS) depressants, which include some narcotic and non-narcotic pain relievers. Furthermore, Abacus is known to inhibit the CYP2D6 enzyme, which may affect how some other medicines are processed by the body.


Q: Can Abacus make certain existing conditions worse?

Official information documents that Abacus is contraindicated (must not be used) in patients with known prolonged QT interval or congenital long QT syndrome due to the risk of serious cardiac events. Use also requires caution in individuals with conditions like prostatic hypertrophy or narrow-angle glaucoma due to the drug's anticholinergic activity.


Q: What should I do if a minor side effect of Abacus doesn't go away?

Regulatory documents state that common side effects, such as drowsiness or dry mouth, are usually temporary and may lessen with continued use. Official instructions note the importance of consulting a healthcare professional if adverse effects persist or worsen.


Q: What are the long-term safety expectations for Abacus?

The effectiveness and safety of continuous use of Abacus for anxiety relief have not been established by systematic clinical studies extending beyond four months. Regulatory documents caution that long-term data for some safety expectations is currently limited.


Q: Can Abacus be taken on an empty stomach?

Yes, official administration guidelines state that the oral forms of Abacus may be taken with or without food.


Q: Why is Abacus sometimes prescribed for different conditions?

Abacus is officially approved for the symptomatic relief of anxiety and tension, and for the management of itching (pruritus) due to allergic conditions. The FDA label also includes its use as a sedative before and after general anesthesia, based on its ability to suppress activity in the central nervous system.


Q: Why are there different strengths of the Abacus product?

Official prescribing information defines different recommended dose ranges for different approved uses, such as for itching versus for anxiety. Different strengths are also used to accommodate necessary dose adjustments for specific patient populations, including children and those with impaired organ function.


Q: How quickly does Abacus usually start working?

According to the official product information, the clinical effects of Abacus are typically noted within 15 to 30 minutes after taking the oral form.


Q: Is Abacus suitable for older adults?

Abacus use is generally not recommended in older adults due to their increased vulnerability to effects like confusion and sedation, and because the body's ability to clear the drug is often reduced. The official guidelines state that if Abacus is used, a reduced initial dose is required for this population, usually starting at the low end of the dosing range.


Q: What kind of studies support the use of Abacus?

The official body of evidence for Abacus includes randomized controlled trials (RCTs) and systematic reviews. Most studies focus on short-term outcomes related to reducing symptoms of allergic itching and generalized anxiety.


Q: Is Abacus a new drug or has it been around for a while?

Abacus is classified as a first-generation antihistamine. Regulatory overviews indicate that clinical trials related to its use for anxiety relief were predominantly conducted in earlier decades, which confirms it has been in use for a long period.


Q: Do I need to change my diet while taking Abacus?

Official prescribing information does not list any mandatory or required dietary changes. The medication can be taken with or without food.


Q: Can Abacus affect my sleep?

Yes, Abacus is known to have a sedative effect and is sometimes used as a sedative premedication. Drowsiness (somnolence) is listed in official documents as a common side effect of the medicine.


Q: Do people using Abacus typically need regular monitoring tests?

Official labeling states that patients with certain risk factors, such as a history or risk factors for QT prolongation, may require monitoring. Additionally, the medication must be stopped at least five days before specific diagnostic procedures, such as allergy skin testing, to prevent interference with test results.


Q: Can Abacus affect my ability to drive?

Official documents warn that due to its known sedative effects, which include drowsiness and impaired psychomotor performance, Abacus may impair a patient's ability to drive or operate machinery. These effects may persist even after the body develops some tolerance.


Q: Can Abacus cause any mood changes?

While Abacus is prescribed to help relieve general anxiety, a mood-related state, official post-marketing reports have documented rare psychiatric effects, including hallucinations. Patients are generally advised to speak with a healthcare provider if any concerning or unexpected changes occur.


Q: Is Abacus only for serious cases of the condition?

Official indications list its use for the symptomatic relief of itching due to allergic conditions and for the relief of anxiety and tension. This indicates the drug is approved for use across a range of symptom severities, not only severe cases.


Q: How is Abacus eliminated from the body?

According to official pharmacokinetics data, Abacus is extensively broken down in the liver into its main active form, called cetirizine. This active form is then primarily removed from the body, mostly unchanged, through the urine.


Q: Do studies show Abacus works better for some people than others?

Official pharmacokinetics data indicates that the rate at which the body clears Abacus and its half-life can vary significantly between different groups of people, such as children, adults, and the elderly. This variability is consistent with the fact that the effects of the medication may differ across these patient groups.

How should Abacus be stored and disposed of?

How to Store and Dispose of Abacus?

The storage and disposal instructions for Abacus (Hydroxyzine Hcl) are based strictly on official regulatory labeling to ensure product stability and safety.

Storage Requirements

Abacus must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container and the cap must remain tightly closed to protect the medicine from moisture. All liquid forms must be protected from freezing, and the product should not be stored in high-humidity areas, such as a bathroom.

Critically, the medicine must always be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Abacus should not be disposed of by flushing it down the toilet or throwing it into the household trash. Official labeling instructs patients to consult a pharmacist for the proper method of disposal, which ensures adherence to local and environmental pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Abacus found in:

A-Z Index: